A carregar...

Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial

AIMS/HYPOTHESIS: In addition to beneficial effects on glycaemia and cardiovascular death, empagliflozin improves adiposity indices. We investigated the effect of empagliflozin on aminotransferases (correlates of liver fat) in individuals with type 2 diabetes. METHODS: Changes from baseline alanine a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Diabetologia
Main Authors: Sattar, Naveed, Fitchett, David, Hantel, Stefan, George, Jyothis T., Zinman, Bernard
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2018
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6133166/
https://ncbi.nlm.nih.gov/pubmed/30066148
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00125-018-4702-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!